1-(氮杂环庚-1-基)-3-甲基-丁烷-1-酮 | 20299-78-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 中文名称: 1-(氮杂环庚-1-基)-3-甲基-丁烷-1-酮
• 英文名称: 1-(Azepan-1-yl)-3-methylbutan-1-one
• CAS: 20299-78-9
• 化学式: C₁₁H₂₁NO
• mdl: MFCD02860668
• 分子量: 183.29
• InChiKey: WSAFHDPKLKXLDO-UHFFFAOYSA-N

物化性质

• 沸点：
  294.8±9.0 °C(Predicted)
• 密度：
  0.933±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] PEPTIDOMIMETIC PROTEASOME INHIBITORS<br/>[FR] INHIBITEURS PEPTIDOMIMÉTIQUES DU PROTÉASOME
  申请人：UNIV CORNELL

  公开号：WO2019075252A1

  公开（公告）日：2019-04-18

  The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I'): where the substituents R, R1, R3 R4, R', W, X, Y, Z, k, and m are as defined herein and where the substituents R, R1, R2, R3, R4, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

  本发明的化合物由具有式（I）和式（I'）的以下化合物表示：其中取代基R、R1、R3、R4、R'、W、X、Y、Z、k和m如本文所定义，取代基R、R1、R2、R3、R4、X、Y、Z和m如本文所定义。这些化合物用于治疗细菌感染、寄生虫感染、真菌感染、癌症、免疫紊乱、自身免疫性疾病、神经退行性疾病和紊乱、炎症性疾病，或肌肉萎缩症，或用于为移植的器官或组织提供免疫抑制。
• HYDROGENATION OF ESTERS WITH RU/BIDENTATE LIGANDS COMPLEXES
  申请人：Saudan Lionel

  公开号：US20100280273A1

  公开（公告）日：2010-11-04

  The present invention relates to the field of catalytic hydrogenation and, more particularly, to the use of Ru complexes with bidentate ligands, having one amino or imino coordinating group and one phosphino coordinating group, in hydrogenation processes for the reduction of esters or lactones into the corresponding alcohol or diol respectively.

  本发明涉及催化氢化领域，更具体地涉及使用具有一种氨基或亚氨基配位基和一种膦配位基的双齿配体的Ru配合物，在氢化过程中将酯或内酯还原为相应的醇或二元醇。
• Peptidomimetic proteasome inhibitors
  申请人：CORNELL UNIVERSITY

  公开号：US11203613B2

  公开（公告）日：2021-12-21

  The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I′): where the substituents R, R1, R3 R4, R′, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R1, R2, R3, R4, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

  本发明的化合物由具有式（I）和式（I′）的下列化合物表示：其中取代基R、R1、R3 R4、R′、W、X、Y、Z、k和m如本文所定义，取代基R、R1、R2、R3、R4、X、Y、Z和m如本文所定义。这些化合物可用于治疗细菌感染、寄生虫感染、真菌感染、癌症、免疫性疾病、自身免疫性疾病、神经退行性疾病、炎症性疾病或肌肉萎缩症，或为移植器官或组织提供免疫抑制。
• PEPTIDOMIMETIC PROTEASOME INHIBITORS
  申请人：CORNELL UNIVERSITY

  公开号：US20200317729A1

  公开（公告）日：2020-10-08

  The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I′): where the substituents R, R 1 , R 3 R 4 , R′, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R 1 , R 2 , R 3 , R 4 , X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.
• US8692022B2
  申请人：——

  公开号：US8692022B2

  公开（公告）日：2014-04-08